What were Ajanta Pharma Ltd's latest quarterly results?
Ajanta Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +18.7% (stable)
- Revenue Growth YoY: +21.5%
- Operating Margin: 23.0% (stable)
Ajanta Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveAverageRe-Entry
In , Ajanta Pharma Ltd (Pharma - Formulators) is outperforming Nifty 500 with +7.8% relative strength. Fundamentals: Average.
Ajanta Pharma Ltd Key Facts
- PE Ratio
- 35.9x
- Market Cap
- ₹37,918 Cr
- PAT Growth YoY
- +19%
- Revenue Growth YoY
- +22%
- OPM
- 23.0%
- RS vs Nifty 500
- +7.8%
PE: Near PeakStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
🌐FII stake decreased 0.6% this quarter
Key Numbers
PAT Growth YoY
+19%
Stable
Revenue YoY
+22%
Accelerating
Operating Margin
23.0%
-200 bps YoY
PE Ratio
35.9
Current Price
₹3,035
Dividend Yield
0.92%
Fundamental Score
43/100
Average
3Y PAT CAGR
+22%
Market Cap
37.9K Cr
Valuation
Slightly Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Ajanta Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +22% | +13% | Accelerating |
| PAT (Net Profit) | +19% | +22% | Stable |
| OPM | 23.0% | -200 bps | Stable |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Ajanta Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Ajanta Pharma Ltd's profit growing or declining?
Ajanta Pharma Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +18.7% (latest quarter)
- PAT Growth QoQ: -2.6% (sequential)
- 3-Year PAT CAGR: +21.6%
- Trend: Stable — consistent growth pattern
What is Ajanta Pharma Ltd's revenue growth trend?
Ajanta Pharma Ltd's revenue growth trend is accelerating.
- Revenue Growth YoY: +21.5%
- Revenue Growth QoQ: +3.4% (sequential)
- 3-Year Revenue CAGR: +13.4%
How is Ajanta Pharma Ltd's operating margin trending?
Ajanta Pharma Ltd's operating margin is stable.
- Current OPM: 23.0%
- OPM Change YoY: -2.0% basis points
- OPM Change QoQ: -5.0% basis points
What is Ajanta Pharma Ltd's 3-year profit and revenue CAGR?
Ajanta Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +21.6%
- 3-Year Revenue CAGR: +13.4%
Is Ajanta Pharma Ltd's growth accelerating or decelerating?
Ajanta Pharma Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +1.1% bps
- Sequential Acceleration: -8.0% bps
What is Ajanta Pharma Ltd's trailing twelve month (TTM) performance?
Ajanta Pharma Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹1,000 Cr
- TTM PAT Growth: +14.8% YoY
- TTM Revenue: ₹5,000 Cr
- TTM Revenue Growth: +17.3% YoY
- TTM Operating Margin: 25.5%
Is Ajanta Pharma Ltd overvalued or undervalued?
Ajanta Pharma Ltd appears slightly undervalued based on our fair value analysis.
- Valuation Signal: Slightly Undervalued
- Current PE: 35.9x
- Price-to-Book: 8.4x
What is Ajanta Pharma Ltd's current PE ratio?
Ajanta Pharma Ltd's current PE ratio is 35.9x.
- Current PE: 35.9x
- Market Cap: 37.9K Cr
- Dividend Yield: 0.92%
How does Ajanta Pharma Ltd's valuation compare to its history?
Ajanta Pharma Ltd's current PE is 35.9x.
- Current PE: 35.9x
- Valuation Assessment: Slightly Undervalued
What is Ajanta Pharma Ltd's price-to-book ratio?
Ajanta Pharma Ltd's price-to-book ratio is 8.4x.
- Price-to-Book (P/B): 8.4x
- Book Value per Share: ₹362
- Current Price: ₹3035
Is Ajanta Pharma Ltd a fundamentally strong company?
Ajanta Pharma Ltd is rated Average with a fundamental score of 43.15/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +21.5% (10% weight)
- PAT Growth YoY: +18.7% (10% weight)
- PAT Growth QoQ: -2.6% (10% weight)
- Margins stable (10% weight)
Is Ajanta Pharma Ltd debt free?
Ajanta Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹260 Cr
What is Ajanta Pharma Ltd's return on equity (ROE) and ROCE?
Ajanta Pharma Ltd's return ratios over recent years
- FY2024: ROCE 32.0%
- FY2025: ROCE 32.0%
- FY2026: ROCE 32.0%
Is Ajanta Pharma Ltd's cash flow positive?
Ajanta Pharma Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹529 Cr
- Free Cash Flow (FCF): ₹100 Cr
- CFO/PAT Ratio: 50% (adequate)
What is Ajanta Pharma Ltd's dividend yield?
Ajanta Pharma Ltd's current dividend yield is 0.92%.
- Dividend Yield: 0.92%
- Current Price: ₹3035
Who holds Ajanta Pharma Ltd shares — promoters, FII, DII?
Ajanta Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 66.3%
- FII (Foreign): 8.3%
- DII (Domestic): 18.4%
- Public: 7.1%
Is promoter holding increasing or decreasing in Ajanta Pharma Ltd?
Ajanta Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 66.3% (Mar 2026)
- Previous Quarter: 66.3% (Dec 2025)
- Change: 0.00% (stable)
How long has Ajanta Pharma Ltd been outperforming Nifty 500?
Ajanta Pharma Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Ajanta Pharma Ltd a new momentum entry or an established outperformer?
Ajanta Pharma Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Is Ajanta Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Ajanta Pharma Ltd may be worth studying
- Earnings growing at +18.7% YoY
- Revenue growth is accelerating — +21.5% YoY
- Valuation: appears slightly undervalued
- Cash flow is positive — CFO ₹529 Cr
What is the investment thesis for Ajanta Pharma Ltd?
Ajanta Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +21.5% YoY
What is the future outlook for Ajanta Pharma Ltd?
Ajanta Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: accelerating
- Margin Trend: stable
- Valuation: Slightly Undervalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.